Actelion Pharmaceuticals US, Inc., a subsidiary of Johnson & Johnson, is a leading biopharmaceutical company headquartered in the United States. Founded in 1997, Actelion has established itself as a pioneer in the development of innovative treatments for pulmonary arterial hypertension (PAH) and other rare diseases. With a strong presence in North America and Europe, the company focuses on delivering unique therapies that improve patients' quality of life. Actelion's core products, including Tracleer and Opsumit, are distinguished by their targeted mechanisms of action and proven efficacy. The company has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which has further solidified its market position. Renowned for its commitment to research and development, Actelion continues to lead the way in addressing unmet medical needs within the biopharmaceutical industry.
We don't have data for Actelion Pharmaceuticals US, Inc., but we can show you information about their parent organization instead.
View parent company